<

Selected Publications and Presentations at Conferences

The clinical results of NA-831 have been or will be published in medical journals and presented at various international conferences including:

  • *Neurogenesis Hypothesis and NA-901 for the treatment of Major Depressive Disorder
    • Neurology World Conference, September 4-6, 2024 in San Francisco, California, USA

  • *A Phase 2 Randomized Placebo-Controlled Clinical Trial to Evaluate the Effect of NA-931 on Weight Loss in Obese Adult Subjects
    • American Diabetes Association-84th Scientific Session- June 21-24, 2024 in Orlando, Florida, USA

  • *A Phase 2 Randomized Placebo-Controlled Clinical Trial to Evaluate the Effect of NA-931 on Weight Loss in Obese Adult Subjects
    • American Association of Clinical Endocrinology, May 9-11, 2024 in New Orleans, Louisiana, USA

  • *Phase 2 clinical trials of NA-931, a new IGF-1/ GLP-1 Agonist for the Treatment of Obesity
    • The 4th International Conference on Diabetes, Endocrinology and Obesity- March 11-12, 2024, Rome, ITALY

  • *Neurogenesis Hypothesis and Clinical Trials of NA-831 for the Treatment of Alzheimer’s Disease and Major Depressive Disorder
    • Clinical Trials on Alzheimer’s Disease (CTAD), October 24-27, 2023 in Boston, MA, USA

  • *A Phase 3 Clinical Trial Protocol to Evaluate the Safety & Efficacy of Combination Therapy of Lecanemab and NA-831
    • Clinical Trials on Alzheimer’s Disease (CTAD), October 24-27, 2023 in Boston, MA, USA

  • *Neurogenesis Hypothesis and Clinical Trials of NA-831 for the Treatment of Alzheimer’s Disease and Major Depressive Disorder
    • Presented at Neurology World Conference- September 15-17, 2023 in Miami, Florida, USA

  • *Amyloid Hypothesis & Neurogenesis Hypothesis: A Case Study Of Phase 2A Clinical Trials Of NA- 831 For The Treatment Of Alzheimer's Disease
    • International Conference on Alzheimer’s Disease and Parkinson’s Disease- March 28-April 1, 2023 Gothenburg, SWEDEN

  • *Amyloid hypothesis: the beginning of the end of a dogma
    • The 6th European Congress on Neurology and Brain Disorders- November 17-18, 2022, Rome, ITALY

  • *Neurogenesis Hypothesis: A case-study – Phase 2A clinical trials of NA-831 for the treatment of Alzheimer’s disease
    • Presented at International Conference on Alzheimer’s disease (AD-PD-2022) – March 15-20, 2022 in Barcelona, SPAIN

  • *A Phase 3 Clinical Trial Protocol to Evaluate the Safety and Efficacy of NA-831 in Patients With Early Alzheimer's Disease
    • Presented at Clinical Trials on Alzheimer’s Disease (CTAD) Conference –November 29-December 2, 2022 in San Francisco, CA, USA

  • *Proposing the Neurogenesis Hypothesis for Alzheimer’s Disease with a case study- Phase 2 Clinical trials of NA-831
    • Alzheimer’s and Dementia, 2022;18(Suppl.10):e061573. https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.061573

  • *A Phase 3 Clinical Trial Protocol to Evaluate the Efficacy and Safety of NA-831 in Subjects with Early Onset of Alzheimer’s Disease
    • Alzheimer’s and Dementia, December 20, 2022 https://doi.org/10.1002/alz.069165

  • *A Randomized Double-Blind Placebo-Controlled Phase 2A Clinical Trial of NA-831 in Patients with MCI and Early Onset of Alzheimer's Disease
    • Alzheimer’s and Dementia, July 1, 2019 https://doi.org/10.1016/j.jalz.2019.08.013

    For further information about our products, please contact us. Contact us